Update on asthma 2024 - what the ENT specialist needs to know
Thieme. All rights reserved..
The lifetime prevalence of 8.6% of asthma in Germany reflects the high medical and socioeconomic impact of the disease. Asthma treatment goals have changed during the last decades: from symptom control to symptom prevention, with highly effective, disease-modifying anti-asthmatic drugs (DMAADs) aiming at asthma remission. In order to achieve this goal, phenotyping of patients (including an evaluation of allergies and type 2 biomarkers) is crucial for personalized treatment. The identification and effective treatment of concomitant diseases, such as allergic rhinitis or chronic rhinosinusitis with nasal polyps (CRSwNP), plays a major role for successful treatment. This underlines the importance of interdisciplinary collaboration of otolaryngologists and respiratory physicians in the management of patients with asthma. This CME article informs the reader about current guidelines on the diagnosis and treatment of asthma, focusing on clinically relevant recommendations for ENT physicians.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:103 |
|---|---|
| Enthalten in: |
Laryngo- rhino- otologie - 103(2024), 3 vom: 27. März, Seite 219-230 |
| Sprache: |
Deutsch |
|---|
| Weiterer Titel: |
Aktuelles zum Asthma 2024 – was der HNO-Arzt wissen muss |
|---|
| Beteiligte Personen: |
Lommatzsch, Marek [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 06.03.2024 Date Revised 29.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1055/a-2189-1732 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369277015 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369277015 | ||
| 003 | DE-627 | ||
| 005 | 20240331001049.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240305s2024 xx |||||o 00| ||ger c | ||
| 024 | 7 | |a 10.1055/a-2189-1732 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1357.xml |
| 035 | |a (DE-627)NLM369277015 | ||
| 035 | |a (NLM)38437838 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a ger | ||
| 100 | 1 | |a Lommatzsch, Marek |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Update on asthma 2024 - what the ENT specialist needs to know |
| 246 | 3 | 3 | |a Aktuelles zum Asthma 2024 – was der HNO-Arzt wissen muss |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.03.2024 | ||
| 500 | |a Date Revised 29.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Thieme. All rights reserved. | ||
| 520 | |a The lifetime prevalence of 8.6% of asthma in Germany reflects the high medical and socioeconomic impact of the disease. Asthma treatment goals have changed during the last decades: from symptom control to symptom prevention, with highly effective, disease-modifying anti-asthmatic drugs (DMAADs) aiming at asthma remission. In order to achieve this goal, phenotyping of patients (including an evaluation of allergies and type 2 biomarkers) is crucial for personalized treatment. The identification and effective treatment of concomitant diseases, such as allergic rhinitis or chronic rhinosinusitis with nasal polyps (CRSwNP), plays a major role for successful treatment. This underlines the importance of interdisciplinary collaboration of otolaryngologists and respiratory physicians in the management of patients with asthma. This CME article informs the reader about current guidelines on the diagnosis and treatment of asthma, focusing on clinically relevant recommendations for ENT physicians | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Rovas, Georgios |e verfasserin |4 aut | |
| 700 | 1 | |a Nastev, Alexander |e verfasserin |4 aut | |
| 700 | 1 | |a Stuck, Boris A |e verfasserin |4 aut | |
| 700 | 1 | |a Pfaar, Oliver |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Laryngo- rhino- otologie |d 1995 |g 103(2024), 3 vom: 27. März, Seite 219-230 |w (DE-627)NLM012616737 |x 1438-8685 |7 nnns |
| 773 | 1 | 8 | |g volume:103 |g year:2024 |g number:3 |g day:27 |g month:03 |g pages:219-230 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1055/a-2189-1732 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 103 |j 2024 |e 3 |b 27 |c 03 |h 219-230 | ||